Estimated generic prices of cancer medicines deemed cost-ineffective in England: A cost estimation analysis

BMJ Open

Volumn 7, Issue 1, 2017, Pages

  Hill, Andrew ^a   Redd, Christopher ^b   Gotham, Dzintars ^c   Erbacher, Isabelle ^c   Meldrum, Jonathan ^d   Harada, Ryo ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DASATINIB; EVEROLIMUS; GEFITINIB; GENERIC DRUG; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ALGORITHM; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CHRONIC MYELOID LEUKEMIA; COST BENEFIT ANALYSIS; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; ENGLAND; EXPIRATION DATE; HEALTH CARE NEED; HEALTH SERVICE; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATENT; PHARMACEUTICAL CARE; PHILADELPHIA CHROMOSOME POSITIVE CELL; RECOMMENDED DRUG DOSE; COMMERCIAL PHENOMENA; ECONOMICS; NEOPLASM;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; COMMERCE; COST-BENEFIT ANALYSIS; DASATINIB; DRUG COSTS; DRUGS, GENERIC; ENGLAND; EVEROLIMUS; HUMANS; NEOPLASMS; QUINAZOLINES;

EID: 85010465470     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-011965     Document Type: Article

References (45)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 2015;385:117-71.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase No. 11, 2013. http://globocan.iarc.fr (accessed 1 Feb 2015).
3. Beaulieu N, Bloom D, Bloom R, et al. Breakaway: the global burden of cancer-challenges and opportunities. A report from the Economist Intelligence Unit, 2009. The Economist. 2009.
4. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155-76.
5. Knaul FM, Frenk J, Shulman L. Closing the cancer divide: a blueprint to expand access in low and middle income countries. Social Science Research Network, 2011.
6. Savage P, Mahmoud S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014. Br J Cancer 2015;112:1037-41.
7. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014;15:e112-18.
8. Lawler M, Le Chevalier T, Murphy MJ, et al. A catalyst for change: the European Cancer Patient's bill of rights. Oncologist 2014;19:217-24.
9. Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14:1165-74.
10. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium-The Just Price. J Clin Oncol 2013;31:3600-4.
11. NICE statistics | News | NICE. https://www.nice.org.uk/news/nice-statistics (accessed 6 Jun 2016).
12. Jack A. Which way now for the Cancer Drugs Fund? BMJ 2014;349: g5524.
13. Hill A, Khoo S, Fortunak J, et al. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis Off Publ Infect Dis Soc Am 2014;58:928-36.
14. Hill A, Gotham D, Cooke G, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad 2015;1:103-10.
15. NHS England. National Cancer Drugs Fund List Ver 6.1. 2015. https://www.england.nhs.uk/wp-content/uploads/2016/02/ncdf-list-01-02-16.pdf (accessed 12 Mar 2016).
16. Import Export Data, Export Import shipment data from Customs. http://www.infodriveindia.com/ (accessed 30 Sep 2015).
17. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/ (accessed 12 Mar 2016).
18. American Cancer Society. Cancer facts & figures 2015. American Cancer Society, 2015.
19. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy | Guidance and guidelines | NICE. http://www.nice.org.uk/guidance/ta295. (accessed 16 Jul 2015).
20. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-24.
21. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii72-7.
22. Alvarnas J, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia. National Comprhensive Cancer Network.
23. Untangling the Web of antiretroviral price reductions: 17th Edition-July 2014. http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-17th-edition-%E2% 80%93-july-2014 (accessed 27 Jul 2015).
24. Rugo HS, Linton KM, Cervi P, et al. A clinician's guide to biosimilars in oncology. Cancer Treat Rev 2016;46:73-9.
25. Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 2014;15:223-8.
26. Hudson J. Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. Int Rev Law Econ 2000;20:205-21.
27. European Commission. Communication from the Commission - executive summary of the Pharmaceutical Sector Inquiry Report. Reference EU Commission report. 8 July 2009 http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication-en.pdf (accessed 17 Mar 2016).
28. Kaplan WA, Ritz LS, Vitello M, et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 2012;106:211-24.
29. Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy 2008;23:500-44.
30. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha declaration: a database analysis. PLoS Med 2012;9: e1001154.
31. WTO | Intellectual property (TRIPS). TRIPS and public health: Compulsory licensing of pharmaceuticals and TRIPS. https://www.wto.org/english/tratop-e/trips-e/public-health-faq-e.htm (accessed 13 Jun 2016).
32. Love J. Remuneration guidelines for non-voluntary use of a patent on medical technologies. World Health Organization Dept of Technical Cooperation for Essential Drugs and Traditional Medicine, 2005.
33. The Patents Act 1977-Publications-GOV.UK. https://www.gov.uk/government/publications/the-patents-act-1977 (accessed 30 Sep 2015).
34. Boseley S. Health secretary urged to tear up patent on breast cancer drug. The Guardian, Oct 2015. https://www.theguardian.com/society/2015/oct/01/health-secretary-breast-cancer-drug-nhs-kadcyla (accessed 10 Dec 2015).
35. Access to Cancer Treatment: A study of medicine pricing issues with recommendations for improving access to cancer medication | Oxfam GB. Policy & Practice. http://policy-practice.oxfam.org. uk/publications/access-to-cancer-treatment-a-study-of-medicinepricing-issues-with-recommendati-344070 (accessed 11 Oct 2015).
36. Medicines Patent Pool. Progress and Achievements of the Medicines Patent Pool 2010-2015. 1 Jul 2015. http://www.medicinespatentpool.org/wp-content/uploads/WEB-Progress-Report-2015-EN.pdf (accessed 7 Jul 2016).
37. Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries | Gilead. http://www.gilead.com/news/press-releases/2014/9/gileadannounces-generic-licensing-agreements-to-increase-access-tohepatitis-c-treatments-in-developing-countries (accessed 11 Oct 2015).
38. 't Hoen E. A victory for global public health in the Indian Supreme Court. J. Public Health Policy 2013;34:370-4.
39. Picot J, Cooper K, Bryant J, et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-204.
40. Pavey T, Hoyle M, Ciani O, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 2012;16:iii-iv, 1-277.
41. Loveman E, Cooper K, Bryant J, et al. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess 2012;16:iii-xiii, 1-137.
42. Pitt M, Crathorne L, Moxham T, et al. Everolimus for the second-line treatment of advanced and/or metastatic renal cell carcinoma. PenTAG, Peninsula Medical School, 2009.
43. Fleeman N, Bagust A, Beale S, et al. Everolimus in combination with an aromatase inhibitor for the treatment of breast cancer after prior endocrine therapy: a Single Technology Appraisal. LRiG, The University of Liverpool, 2013.
44. Brown T, Boland A, Bagust A, et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): a Single Technology Appraisal. LRiG, The University of Liverpool, 2009.
45. British National Formulary. BMJ Group & Pharmaceutical Press.